Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness

PI: Tamar Polonsky, MD
Co-PI: David Meltzer, MD, PhD

CAPriCORN is participating in a national study along with PCORnet and other CDRNs on the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Terms Effectiveness (ADAPTABLE). This trial will compare the effectiveness of two daily doses of aspirin widely used to prevent heart attacks and strokes in individuals living with heart disease. This study will help improve care and outcomes for patients with heart disease and could prevent as many as 88,800 deaths per year around the world.

CAPriCORN is using an engagement and outreach strategic approach for the ADAPTABLE trial with three primary paths to engaging patients:

  • Identification of potential participants using the computable phenotype and contact via a combination of phones, email, and mail
  • A traditional clinic-based recruitment strategy
  • A novel community-based recruitment strategy through engagement of Pastors4PCOR and community health workers at Sinai Urban Health Institute

To learn more about ADAPTABLE, please visit: